PCN126 A Cost IMPACT Analysis of Clonoseq® As a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic in Multiple Myeloma in Germany

Abstract

Authors

S. Walzer L. Vollmer S. Krenberger F. Rosseel T. Hewitt B. Eckert

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×